Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

BackgroundNeoadjuvant chemotherapy (nCT) and chemoradiotherapy (nCRT) are the standard treatments in patients with resectable locally advanced esophageal squamous cell carcinoma (ESCC). Adding PD-1 inhibitor to the chemotherapy has shown significant clinical benefits in first-line treatment of advan...

Full description

Bibliographic Details
Main Authors:	Huilai Lv, Yang Tian, Jiachen Li, Chao Huang, Bokang Sun, Chunyue Gai, Zhenhua Li, Ziqiang Tian
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-04-01
Series:	Frontiers in Oncology
Subjects:	esophageal squamous cell carcinoma pathologic complete response combination therapy immune checkpoint inhibitors sintilimab
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2022.864533/full

Similar Items

The survival outcomes of neoadjuvant sintilimab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma
by: Huilai Lv, et al.
Published: (2023-01-01)

Neoadjuvant sintilimab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, phase 2 trial
by: Zhi Zhang, et al.
Published: (2022-10-01)

Cost-effectiveness analysis of sintilimab plus chemotherapy for advanced or metastatic esophageal squamous cell carcinoma
by: Maojin You, et al.
Published: (2022-12-01)

Pre-immunotherapy radiotherapy enhanced the efficacy of multi-line sintilimab in unresectable advanced esophageal squamous cell carcinoma
by: Shuhui Xu, et al.
Published: (2023-02-01)

First-line sintilimab plus chemotherapy in locally advanced or metastatic esophageal squamous cell carcinoma: A cost-effectiveness analysis from China
by: Jian Shen, et al.
Published: (2022-12-01)

Successful neoadjuvant chemotherapy plus sintilimab for locally advanced cervical cancer: case series and review of the literature
by: Linlin Liu, et al.
Published: (2023-09-01)

Case Report: A Case of Sintilimab-Induced Cystitis/Ureteritis and Review of Sintilimab-Related Adverse Events
by: Lingfang Tu, et al.
Published: (2021-12-01)

Cost-Effectiveness Analysis of Sintilimab Combined with Chemotherapy Versus Chemotherapy Alone as the First-Line Treatment for Advanced Esophageal Cancer
by: Zhuo-Miao Ye, et al.
Published: (2022-11-01)

Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC
by: Pingyu Chen, et al.
Published: (2022-08-01)

Sintilimab-induced inflammatory myopathy in a patient with esophageal cancer: a case report
by: Guo Hong, et al.
Published: (2023-10-01)

Sintilimab-Induced Myocarditis Overlapping Myositis in a Patient With Metastatic Thymoma: A Case Report
by: Zi-xuan Yang, et al.
Published: (2021-12-01)

Sintilimab Plus Apatinib and Chemotherapy as Second‑/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial
by: Le Zhang, et al.
Published: (2023-03-01)

Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: A prospective, open-label, single-arm, phase II clinical study
by: Dailong Li, et al.
Published: (2022-08-01)

Comparison of neoadjuvant immunotherapy versus routine neoadjuvant therapy for patients with locally advanced esophageal cancer: A systematic review and meta-analysis
by: Hao Qin, et al.
Published: (2023-03-01)

Toxic Epidermal Necrolysis and Stevens - Johnson Syndrome Following Sintilimab Administration in a Non-Small Cell Lung Cancer Patient: A Case Report
by: Jiang Z, et al.
Published: (2023-11-01)

Comparison of Neoadjuvant Immunotherapy Plus Chemotherapy versus Neoadjuvant Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma: A Propensity Score Matching Study
by: Zhao J, et al.
Published: (2023-08-01)

Achieving complete remission in metastatic hepatocellular carcinoma with sintilimab plus sorafenib therapy followed by hepatic resection: a case report
by: Kai Cui, et al.
Published: (2024-02-01)

Efficacy and safety of sintilimab plus XELOX as a neoadjuvant regimen in patients with locally advanced gastric cancer: A single-arm, open-label, phase II trial
by: Honghai Guo, et al.
Published: (2022-08-01)

Neoadjuvant sintilimab combined with chemotherapy in resectable locally advanced non-small cell lung cancer: case series and literature review
by: Cunli Yin, et al.
Published: (2023-09-01)

Neoadjuvant immune checkpoint inhibitor in combination with chemotherapy or chemoradiotherapy in resectable esophageal cancer: A systematic review and meta-analysis
by: He Wang, et al.
Published: (2022-09-01)

Development and validation of a nomogram for predicting immune‐related pneumonitis after sintilimab treatment
by: Baohui Hong, et al.
Published: (2024-02-01)

Case report: Robust response to sintilimab in advanced distal cholangiocarcinoma with PD-L1 expression and DNA damage repair
by: Wenguang He, et al.
Published: (2024-04-01)

Sintilimab plus Lenvatinib conversion therapy for intermediate/locally advanced hepatocellular carcinoma: A phase 2 study
by: Lijun Wang, et al.
Published: (2023-02-01)

Cost‐effectiveness analysis of sintilimab plus IBI305 versus sorafenib for unresectable hepatic cell carcinoma in China
by: Zhe Xu, et al.
Published: (2023-07-01)

Sintilimab-Induced Myocarditis in a Patient with Gastric Cancer: A Case Report and Literature Review
by: Xin Liu, et al.
Published: (2023-10-01)

Efficacy and safety of pembrolizumab versus sintilimab treatment in patients with advanced squamous lung cancer: A real-world study in China
by: Wenyu Yang, et al.
Published: (2023-04-01)

A Case of Complete Remission in Proficient Mismatch Repair (pMMR) Advanced Colon Cancer Treated with Sintilimab and XELOX
by: Zhu J, et al.
Published: (2023-02-01)

Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma
by: Ting Zhou, et al.
Published: (2022-11-01)

Clinical activity and safety of sintilimab, bevacizumab, and TMZ in patients with recurrent glioblastoma
by: Yinghao Lu, et al.
Published: (2024-01-01)

Efficacy and Safety of Fruquintinib Combined with Sintilimab in Treatment of Advanced Microsatellite Stable Colorectal Cancer
by: LI Shan, et al.
Published: (2023-12-01)

Unexpected favorable outcome to sintilimab plus bevacizumab in an EGFR‐mutated non‐small cell lung cancer patient: A case report
by: Yiruo Zhang, et al.
Published: (2020-09-01)

Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma
by: Lulu Liu, et al.
Published: (2023-01-01)

Immune Thrombocytopenia Induced by Sintilimab in Lung Cancer:  A Case Report and Literature Review
by: Jingjing CAI, et al.
Published: (2023-09-01)

Efficacy and safety of sintilimab plus bevacizumab in metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy: an open-label phase 2 studyResearch in context
by: Nian Lu, et al.
Published: (2023-08-01)

Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
by: Ye Peng, et al.
Published: (2022-02-01)

Severe immune‐related hyperthermia followed by immune‐related pneumonitis with PD‐1 inhibitor (sintilimab) in small cell lung cancer: A case report
by: Yi‐hui Li, et al.
Published: (2021-06-01)

Neoadjuvant immunotherapy for resectable esophageal cancer: A review
by: Qing Li, et al.
Published: (2022-12-01)

Anlotinib combined with Sintilimab is win-win cooperation for primary squamous cell carcinoma of the thyroid: A case report and literature review
by: Zichang Liu, et al.
Published: (2023-03-01)

Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study
by: Lei Zhao, et al.
Published: (2022-06-01)

Efficacy of TACE Combined with Lenvatinib Plus Sintilimab for Hepatocellular Carcinoma with Tumor Thrombus in the Inferior Vena Cava and/or Right Atrium
by: Ning S, et al.
Published: (2023-09-01)